Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 7Phase 1/2 3Phase 2/3 2Phase 1 2

Status

Completed 2Unknown 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 22Lymphoid 10Genitourinary 3Sarcoma 1Myeloid 1Gynecologic 1

Conditions

Prostatic Neoplasms 3Neoplasms 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Mitoxantrone × Genitourinary × Clear all
NCT00331344 2017-10-31

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

National Cancer Institute (NCI)

Phase 1/2 Completed
100 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00770848 2014-03-10

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Amgen

Phase 1/2 Completed
162 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00003183 2013-12-04

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
64 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡